Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26

Benzinga Newsdesk www.benzinga.com Positive 55.8%

Neg 0% Neu 0% Pos 55.8%

Wells Fargo analyst Tianqi Hang initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Overweight rating and announces Price Target of $26.